Medicis Pharmaceutical Corp. (MRX) Tops Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $65.05 --0%
Revenue Growth %: +21.2%
Financial Fact:
Net income (loss): 937K
Today's EPS Names:
TFS, PBNK, FNRN, More
Revenue Growth %: +21.2%
Financial Fact:
Net income (loss): 937K
Today's EPS Names:
TFS, PBNK, FNRN, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NASDAQ: MRX) reported Q1 EPS of $0.91, $0.14 better than the analyst estimate of $0.77. Revenue for the quarter came in at $467.3 million versus the consensus estimate of $428.46 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TFS Financial (TFSL) Reports In-Line Q4 EPS
- Citi cuts Stryker price target to $315 from $360
- Citi reiterates buy rating on Coinbase with $230 target
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
